PMID: 29466692Feb 22, 2018Paper

Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma -- a clinical update

Discovery Medicine
Van Anh TrinhWen-Jen Hwu

Abstract

Since their approval by regulatory agencies worldwide, the anti-PD-1 monoclonal antibodies (mAbs), as monotherapy or in combination with ipilimumab, have become the standard frontline therapy for advanced BRAF-wild-type melanoma and an eminent rival to targeted therapy in the first-line setting for unresectable BRAF-mutated melanoma. Mature survival data from randomized phase 3 trials have emerged, confirming their position in the current treatment schema for advanced melanoma. Recently, the clinical utility of anti-PD-1 agents has extended into other disease settings, such as resected high-risk melanomas, non-cutaneous subtypes, and brain metastases. How to best combat resistance to anti-PD-1 mAbs remains the major focus of clinical investigations. This review aims to provide an update on the recent progress and current challenges relating to the clinical application of anti-PD-1 agents in the treatment of advanced melanoma.

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Related Papers

Current Opinion in Oncology
Florentia DimitriouJoanna Mangana
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Ryan J Sullivan, Keith T Flaherty
Future Oncology
Fabio GomesPaul Lorigan
Contemporary Oncology Współczesna Onkologia
Jacek Mackiewicz
© 2022 Meta ULC. All rights reserved